/ENVB
ENVB Stock - Enveric Biosciences, Inc.
Healthcare|BiotechnologyNASDAQ
$5.08+0.49%
+$0.03 (+0.49%) • Dec 19
55
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $5.59
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ENVB
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$5.03 – $5.13
TARGET (TP)$5.84
STOP LOSS$4.67
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.27
52W High$1444.50
52W Low$4.55
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-337,489 | $-408,030 | $-435,201 | $-681,612 | $-120,872 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-9,632,266 | $-16,448,440 | $-19,961,444 | $-25,944,502 | $-5,617,317 |
| Net Income | $-9,574,987 | $-17,291.732 | $-18,504,347 | $-48,976,896 | $-6,864,676 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-228.48 | $-97.08 | $-87.72 | $-1244.28 | $-666.00 |
Company Overview
Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosciences, Inc. is headquartered in Naples, Florida.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
ENVBBeat Rate
59%
Last 17 quarters
Avg Surprise
-638.6%
EPS vs Estimate
Beats / Misses
10/6
1 met exactly
Latest EPS
$-10.81
Q4 2025
EPS Surprise History
Q1 24
+5.8%
$-21.89vs$-23.24
Q2 24
0.0%
$-9.15vs$-9.15
Q3 24
+54.5%
$-3.75vs$-8.25
Q4 24
+53.8%
$-3.60vs$-7.80
Q1 25
-534.5%
$-21.89vs$-3.45
Q2 25
+79.7%
$-1.22vs$-6.00
Q3 25
+81.5%
$-11.64vs$-63.00
Q4 25
+82.8%
$-10.81vs$-63.00
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 26, 2026 | — | — | — | — |
Q4 2025 | Nov 14, 2025 | $-63.00 | $-10.81 | +82.8% | ✓ BEAT |
Q3 2025 | Aug 14, 2025 | $-63.00 | $-11.64 | +81.5% | ✓ BEAT |
Q2 2025 | May 14, 2025 | $-6.00 | $-1.22 | +79.7% | ✓ BEAT |
Q1 2025 | Mar 31, 2025 | $-3.45 | $-21.89 | -534.5% | ✗ MISS |
Q4 2024 | Nov 14, 2024 | $-7.80 | $-3.60 | +53.8% | ✓ BEAT |
Q3 2024 | Aug 12, 2024 | $-8.25 | $-3.75 | +54.5% | ✓ BEAT |
Q2 2024 | May 14, 2024 | $-9.15 | $-9.15 | 0.0% | = MET |
Q1 2024 | Mar 25, 2024 | $-23.24 | $-21.89 | +5.8% | ✓ BEAT |
Q4 2023 | Nov 13, 2023 | $-28.94 | $-19.49 | +32.7% | ✓ BEAT |
Q3 2023 | Aug 14, 2023 | $-0.65 | $-45.58 | -6912.3% | ✗ MISS |
Q2 2023 | Jun 8, 2023 | — | $-6.76 | — | — |
Q2 2023 | May 15, 2023 | $-33.45 | $-33.28 | +0.5% | ✓ BEAT |
Q4 2022 | Nov 14, 2022 | $-4.00 | $-21.89 | -447.3% | ✗ MISS |
Q3 2022 | Aug 12, 2022 | $-3.83 | $-40.93 | -968.7% | ✗ MISS |
Q2 2022 | May 13, 2022 | $-6.00 | $-82.46 | -1274.3% | ✗ MISS |
Q1 2022 | Mar 31, 2022 | $-8.00 | $-104.95 | -1211.9% | ✗ MISS |
Q4 2021 | Nov 15, 2021 | $-8.00 | $-6.00 | +25.0% | ✓ BEAT |
Q3 2021 | Aug 13, 2021 | $-8.75 | $-2.00 | +77.1% | ✓ BEAT |
Q2 2021 | May 18, 2021 | — | $-149.93 | — | — |
Latest News
Enveric Biosciences Announces Immediate Warrant Exercise, Raising ~$3.1M Gross Proceeds At Reduced $7.05/Share Price
➖ NeutralBenzinga•Dec 11, 2025, 06:46 PM
ENVB stock has given up its prior gain. Enveric Biosciences shares were trading higher after the company received notice from the U.S. Patent and Trademark Office for a patent application covering its EVM301 series drug candidates.
➖ NeutralBenzinga•Dec 9, 2025, 01:33 PM
Enveric Biosciences shares are trading higher after the company received notice from the U.S. Patent and Trademark Office for a patent application covering its EVM301 series drug candidates.
📈 PositiveBenzinga•Dec 9, 2025, 01:02 PM
Enveric Biosciences Receives Notice From US Patent And Trademark Office For Patent Application Pertaining To EVM301 Series Of Drug Candidates
📈 PositiveBenzinga•Dec 9, 2025, 01:01 PM
Enveric Biosciences Receives Notice of Allowance From U.S. Patent And Trademark Office For EVM401 Series Of Molecules For Mental Health Disorders Treatment
📈 PositiveBenzinga•Nov 26, 2025, 01:03 PM
Enveric Biosciences Q3 EPS $(10.81) Up From $(43.10) YoY
📈 PositiveBenzinga•Nov 14, 2025, 09:09 PM
Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times
➖ NeutralBenzinga•Oct 28, 2025, 12:55 PM
Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending
➖ NeutralBenzinga•Oct 27, 2025, 11:50 PM
Enveric Biosciences To Implement 1-For-12 Reverse Stock Split, Trading On Split-Adjusted Basis Starting October 28, 2025
📉 NegativeBenzinga•Oct 23, 2025, 12:16 PM
Enveric Biosciences Secures USPTO Patent For Neuroplastogenic Compounds, Expanding IP Assets For Potential Treatment Of Mental Health Disorders
📈 PositiveBenzinga•Oct 16, 2025, 12:38 PM
Enveric Biosciences Hires Fish And Richardson P.C. To Defend Its U.S. Patent With Claims Relevant To Bretisilocin
➖ NeutralBenzinga•Oct 15, 2025, 12:09 PM
Enveric Biosciences Board Authorizes Capital Markets Committee To Explore And Negotiate Non-Binding Term Sheets For Potential Digital Asset Treasury Strategy Opportunities
➖ NeutralBenzinga•Oct 14, 2025, 01:03 PM
'Psychedelics Show Promise As An 'Entirely New Type Of Anti-Inflammatory Treatment,' Research Suggests' - Marijuana Moment
📈 PositiveBenzinga•Oct 13, 2025, 05:28 PM•Also: , ,
Enveric Biosciences shares are trading higher after the company announced its EB-003 manufacturing milestones.
📈 PositiveBenzinga•Oct 2, 2025, 06:55 PM
'New York Lawmakers Hold Hearing Psilocybin's Medical Benefits Amid Broader Debate Over Psychedelics Reform' - Marijuana Moment
➖ NeutralBenzinga•Oct 2, 2025, 03:03 PM•Also: , ,
Enveric Biosciences Completes Key Manufacturing Milestones In Support Of Planned IND And Clinical Trials
📈 PositiveBenzinga•Oct 2, 2025, 12:46 PM
Enveric Biosciences Selling Stockholders Are Offering On A Resale Basis An Aggregate Of 4.8M Shares Of Common Stock
➖ NeutralBenzinga•Sep 29, 2025, 08:55 PM
Enveric Biosciences shares are trading lower after the company announced an exercise of warrants for $2.2 million gross proceeds.
➖ NeutralBenzinga•Sep 17, 2025, 01:30 PM
Enveric Biosciences Raises ~$2.2M Via Immediate Exercise Of 1,212,499 Series A & 1,212,499 Series B Warrants At Reduced Excersize Price Of $0.915; Company Will Issue New Unregistered Series C Warrants To Purchase Up To 2,424,998 Shares Of Common Stock And New Unregistered Series D Warrants To Purchase Up To 2,424,998 Shares Of Common Stock
➖ NeutralBenzinga•Sep 17, 2025, 01:27 PM
Enveric Biosciences Announces Publication Of Two Peer-Reviewed Papers Showcasing Bioproduction Strategies For Developing Therapeutic Compounds
📈 PositiveBenzinga•Sep 17, 2025, 12:11 PM
Frequently Asked Questions about ENVB
What is ENVB's current stock price?
Enveric Biosciences, Inc. (ENVB) is currently trading at $5.08 per share. The stock has moved +0.49% today.
What is the analyst price target for ENVB?
No analyst price targets are currently available for this stock.
What sector is Enveric Biosciences, Inc. in?
Enveric Biosciences, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ENVB's market cap?
Enveric Biosciences, Inc. has a market capitalization of $0.00 billion, making it a small-cap company.
Does ENVB pay dividends?
No, Enveric Biosciences, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAZTR
Azitra, Inc.
$0.29
Mkt Cap: $0.0B
HEPA
Hepion Pharmaceuticals, Inc.
$0.07
Mkt Cap: $0.0B
INDP
Indaptus Therapeutics, Inc.
$2.03
Mkt Cap: $0.0B
JSPR
Jasper Therapeutics, Inc.
$1.86
Mkt Cap: $0.0B
ONCO
Onconetix, Inc.
$1.77
Mkt Cap: $0.0B
SCNI
Scinai Immunotherapeutics Ltd.
$0.79
Mkt Cap: $0.0B
SLRX
Salarius Pharmaceuticals, Inc.
$0.69
Mkt Cap: $0.0B
SLXN
Silexion Therapeutics Ltd.
$2.40
Mkt Cap: $0.0B
SPRC
SciSparc Ltd.
$1.46
Mkt Cap: $0.0B
ZVSA
ZyVersa Therapeutics, Inc.
$0.14
Mkt Cap: $0.0B
Explore stocks similar to ENVB for comparison